RE:RE:RE:RE:RE:RE:This constant selling...........But Hutchmed, Li Ka-shing's cancer drug company might...
Hutchmed was expecting FDA approval for their first anti-cancer drug in the US, surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumours. Instead they got a complete response letter from the FDA on May 2. Hutchmed had built a small US commercialization team in anticipation of approval. So now they have a US team in place but no approved drug to commercialize.
Rumpl3StiltSkin wrote: I think we will get AA early 2nd qtr 2023. Yes Laser. I think that is what they mean by commercial revenues. Selling 1433 to urologists in the US with an, conditionally, FDA approved product. They will likely need some partner for this as they don't currently have the resources to market distribute and manufacture all the different pieces of their ACT. At least not to Scale...